Domain swapping in N-truncated human cystatin C

Robert Janowski1, Magnus Abrahamson, Anders Grubb

  • 1Department of Crystallography, Faculty of Chemistry, A. Mickiewicz University, Grunwaldzka 6, 60-780 Poznan, Poland.

Insights

Human cystatin C (HCC) oligomerization causes amyloid deposits. N-truncated HCC forms dimers via 3D domain swapping, similar to full-length HCC, but with structural variations leading to octameric assemblies.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Neuroscience

Background:

  • Human cystatin C (HCC) is a protease inhibitor found in body fluids, notably cerebrospinal fluid.
  • Oligomerization of HCC can lead to amyloid deposits, causing amyloidosis, especially with the Leu68Gln variant.
  • N-terminally truncated HCC (THCC) is the predominant form in amyloid deposits, likely due to proteolytic activity in cerebrospinal fluid.

Purpose of the Study:

  • To determine the crystal structure of N-truncated human cystatin C (THCC).
  • To investigate the mechanism of dimerization and oligomerization of THCC in amyloid deposits.
  • To compare the structural features of THCC dimers with those of full-length HCC.

Main Methods:

  • X-ray crystallography to determine the 3D structure of N-truncated HCC.
  • Analysis of protein quaternary structure and intermolecular interactions.
  • Comparison of structural data with full-length HCC.

Main Results:

  • The crystal structure of THCC reveals dimerization through 3D domain swapping, similar to full-length HCC.
  • THCC dimers exhibit structural variability and form closed octameric assemblies.
  • These octamers are structurally identical to those formed by full-length HCC, involving intermolecular beta-sheet formation.

Conclusions:

  • 3D domain swapping is a conserved mechanism for HCC oligomerization, leading to amyloid formation.
  • The structural flexibility of THCC dimers contributes to the formation of stable octameric assemblies.
  • Understanding THCC structure provides insights into the molecular basis of cystatin C-related amyloidosis.